Emirhan Nemutlu1, Song Zhang2, Yi-Zhou Xu3, Andre Terzic2, Li Zhong3, Petras D Dzeja2, Yong-Mei Cha4. 1. Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota; Departments of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota; Department of Analytical Chemistry, Faculty of Pharmacy, University of Hacettepe, Ankara, Turkey. 2. Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota; Departments of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota. 3. Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota. 4. Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: ycha@mayo.edu.
Abstract
BACKGROUND: Heart failure (HF) is associated with ventricular dyssynchrony and energetic inefficiency, which can be alleviated by cardiac resynchronization therapy (CRT). The aim of this study was to determine the metabolomic signature in HF and its prognostic value regarding the response to CRT. METHODS AND RESULTS: This prospective study consisted of 24 patients undergoing CRT for advanced HF and 10 control patients who underwent catheter ablation for supraventricular arrhythmia but not CRT. Blood samples were collected before and 3 months after CRT. Metabolomic profiling of plasma samples was performed with the use of gas chromatography-mass spectrometry and nuclear magnetic resonance. The plasma metabolomic profile was altered in the HF patients, with a distinct panel of metabolites, including Krebs cycle and lipid, amino acid, and nucleotide metabolism. CRT improved the metabolomic profile. The succinate-glutamate ratio, an index of Krebs cycle activity, improved from 0.58 ± 0.13 to 2.84 ± 0.60 (P < .05). The glucose-palmitate ratio, an indicator of the balance between glycolytic and fatty acid metabolism, increased from 0.96 ± 0.05 to 1.54 ± 0.09 (P < .01). Compared with nonresponders to CRT, responders had a distinct baseline plasma metabolomic profile, including higher isoleucine, phenylalanine, leucine, glucose, and valine levels and lower glutamate levels at baseline (P < .05). CONCLUSIONS: CRT improves the plasma metabolomic profile of HF patients, indicating harmonization of myocardial energy substrate metabolism. CRT responders may have a favorable metabolomic profile as a potential biomarker for predicting CRT outcome. Published by Elsevier Inc.
BACKGROUND:Heart failure (HF) is associated with ventricular dyssynchrony and energetic inefficiency, which can be alleviated by cardiac resynchronization therapy (CRT). The aim of this study was to determine the metabolomic signature in HF and its prognostic value regarding the response to CRT. METHODS AND RESULTS: This prospective study consisted of 24 patients undergoing CRT for advanced HF and 10 control patients who underwent catheter ablation for supraventricular arrhythmia but not CRT. Blood samples were collected before and 3 months after CRT. Metabolomic profiling of plasma samples was performed with the use of gas chromatography-mass spectrometry and nuclear magnetic resonance. The plasma metabolomic profile was altered in the HF patients, with a distinct panel of metabolites, including Krebs cycle and lipid, amino acid, and nucleotide metabolism. CRT improved the metabolomic profile. The succinate-glutamate ratio, an index of Krebs cycle activity, improved from 0.58 ± 0.13 to 2.84 ± 0.60 (P < .05). The glucose-palmitate ratio, an indicator of the balance between glycolytic and fatty acid metabolism, increased from 0.96 ± 0.05 to 1.54 ± 0.09 (P < .01). Compared with nonresponders to CRT, responders had a distinct baseline plasma metabolomic profile, including higher isoleucine, phenylalanine, leucine, glucose, and valine levels and lower glutamate levels at baseline (P < .05). CONCLUSIONS: CRT improves the plasma metabolomic profile of HF patients, indicating harmonization of myocardial energy substrate metabolism. CRT responders may have a favorable metabolomic profile as a potential biomarker for predicting CRT outcome. Published by Elsevier Inc.
Authors: Frieder Braunschweig; Jens Sörensen; Helene von Bibra; Arne Olsson; Lars Rydén; Bengt Långström; Cecilia Linde Journal: Am J Cardiol Date: 2003-07-01 Impact factor: 2.778
Authors: David S Wishart; Michael J Lewis; Joshua A Morrissey; Mitchel D Flegel; Kevin Jeroncic; Yeping Xiong; Dean Cheng; Roman Eisner; Bijaya Gautam; Dan Tzur; Summit Sawhney; Fiona Bamforth; Russ Greiner; Liang Li Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2008-05-08 Impact factor: 3.205
Authors: Ashish Gupta; Ashwin Akki; Yibin Wang; Michelle K Leppo; V P Chacko; D Brian Foster; Viviane Caceres; Sa Shi; Jonathan A Kirk; Jason Su; Shenghan Lai; Nazareno Paolocci; Charles Steenbergen; Gary Gerstenblith; Robert G Weiss Journal: J Clin Invest Date: 2011-12-27 Impact factor: 14.808
Authors: Giulio Agnetti; Nina Kaludercic; Lesley A Kane; Steven T Elliott; Yurong Guo; Khalid Chakir; Daya Samantapudi; Nazareno Paolocci; Gordon F Tomaselli; David A Kass; Jennifer E Van Eyk Journal: Circ Cardiovasc Genet Date: 2009-11-17
Authors: Sarah Gleeson; Yi-Wen Liao; Clementina Dugo; Andrew Cave; Lifeng Zhou; Zina Ayar; Jonathan Christiansen; Tony Scott; Liane Dawson; Andrew Gavin; Todd T Schlegel; Patrick Gladding Journal: PLoS One Date: 2017-03-30 Impact factor: 3.240
Authors: K Sattler; M Behnes; C Barth; A Wenke; B Sartorius; I El-Battrawy; K Mashayekhi; J Kuschyk; U Hoffmann; T Papavasiliu; C Fastner; S Baumann; S Lang; X Zhou; G Yücel; M Borggrefe; I Akin Journal: Metabolomics Date: 2017-09-20 Impact factor: 4.290
Authors: Christian Fastner; Michael Behnes; Benjamin Sartorius; Annika Wenke; Siegfried Lang; Gökhan Yücel; Katherine Sattler; Jonas Rusnak; Ahmad Saleh; Christian Barth; Kambis Mashayekhi; Ursula Hoffmann; Martin Borggrefe; Ibrahim Akin Journal: Int J Mol Sci Date: 2018-02-07 Impact factor: 5.923